Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 5 studies | 22% ± 7% | |
| astrocyte | 4 studies | 19% ± 3% | |
| hematopoietic precursor cell | 3 studies | 20% ± 5% | |
| GABAergic neuron | 3 studies | 28% ± 4% | |
| glutamatergic neuron | 3 studies | 34% ± 7% | |
| oligodendrocyte precursor cell | 3 studies | 23% ± 4% | |
| dendritic cell | 3 studies | 18% ± 2% | |
| erythroblast | 3 studies | 21% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| pancreas | 100% | 1800.12 | 327 / 328 | 100% | 23.25 | 178 / 178 |
| skin | 100% | 11129.36 | 1809 / 1809 | 99% | 35.07 | 469 / 472 |
| thymus | 100% | 1944.93 | 652 / 653 | 100% | 28.13 | 602 / 605 |
| bladder | 100% | 2173.14 | 21 / 21 | 99% | 28.88 | 500 / 504 |
| prostate | 100% | 1920.67 | 245 / 245 | 99% | 19.31 | 497 / 502 |
| brain | 99% | 1364.33 | 2615 / 2642 | 100% | 32.26 | 705 / 705 |
| uterus | 100% | 2413.46 | 170 / 170 | 98% | 33.85 | 448 / 459 |
| breast | 100% | 2083.05 | 459 / 459 | 97% | 34.98 | 1090 / 1118 |
| lung | 100% | 2100.37 | 578 / 578 | 97% | 31.47 | 1126 / 1155 |
| esophagus | 100% | 2251.10 | 1444 / 1445 | 97% | 29.16 | 178 / 183 |
| kidney | 100% | 2236.08 | 89 / 89 | 97% | 31.15 | 874 / 901 |
| intestine | 100% | 2186.68 | 966 / 966 | 97% | 23.14 | 510 / 527 |
| stomach | 100% | 1563.70 | 359 / 359 | 97% | 22.04 | 276 / 286 |
| adrenal gland | 100% | 1572.98 | 258 / 258 | 93% | 15.88 | 214 / 230 |
| ovary | 100% | 1677.14 | 180 / 180 | 86% | 11.93 | 368 / 430 |
| liver | 89% | 757.42 | 201 / 226 | 71% | 15.64 | 287 / 406 |
| adipose | 100% | 2435.07 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 100% | 26.54 | 80 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 53.53 | 29 / 29 |
| muscle | 100% | 1918.70 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 2529.49 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 38.28 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 28.40 | 1 / 1 |
| blood vessel | 100% | 2280.58 | 1334 / 1335 | 0% | 0 | 0 / 0 |
| heart | 98% | 1131.14 | 842 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 80% | 1501.27 | 741 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0009410 | Biological process | response to xenobiotic stimulus |
| GO_0009636 | Biological process | response to toxic substance |
| GO_0000209 | Biological process | protein polyubiquitination |
| GO_0006508 | Biological process | proteolysis |
| GO_0043418 | Biological process | homocysteine catabolic process |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_0005829 | Cellular component | cytosol |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0004180 | Molecular function | carboxypeptidase activity |
| GO_0004197 | Molecular function | cysteine-type endopeptidase activity |
| GO_0008234 | Molecular function | cysteine-type peptidase activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0042802 | Molecular function | identical protein binding |
| GO_0070005 | Molecular function | cysteine-type aminopeptidase activity |
| GO_0004177 | Molecular function | aminopeptidase activity |
| Gene name | BLMH |
| Protein name | Bleomycin hydrolase (BH) (BLM hydrolase) (BMH) (EC 3.4.22.40) Bleomycin hydrolase (EC 3.4.22.40) Bleomycin hydrolase |
| Synonyms | |
| Description | FUNCTION: The normal physiological role of BLM hydrolase is unknown, but it catalyzes the inactivation of the antitumor drug BLM (a glycopeptide) by hydrolyzing the carboxamide bond of its B-aminoalaninamide moiety thus protecting normal and malignant cells from BLM toxicity. . |
| Accessions | ENST00000580709.1 ENST00000577623.5 Q13867 K7EMJ3 K7ENH5 J3KSD8 ENST00000581037.5 K7ES02 ENST00000261714.11 J3KS79 ENST00000584603.2 ENST00000578090.5 ENST00000577290.1 K7ESE8 |